Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Trexquant Investment LP

Trexquant Investment LP cut its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 85.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 22,527 shares of the company’s stock after selling 136,734 shares during the quarter. Trexquant Investment LP’s holdings in Nurix Therapeutics were worth $424,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. US Bancorp DE boosted its holdings in Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after acquiring an additional 842 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Nurix Therapeutics in the 4th quarter worth about $209,000. EP Wealth Advisors LLC acquired a new position in shares of Nurix Therapeutics in the 3rd quarter valued at about $240,000. EntryPoint Capital LLC purchased a new stake in shares of Nurix Therapeutics during the 4th quarter worth about $266,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Nurix Therapeutics by 21.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company’s stock worth $283,000 after purchasing an additional 2,632 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wells Fargo & Company reduced their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday. Leerink Partnrs raised shares of Nurix Therapeutics to a “hold” rating in a research report on Monday, March 17th. Needham & Company LLC cut their price objective on Nurix Therapeutics from $28.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday. Royal Bank of Canada upped their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Finally, Leerink Partners started coverage on Nurix Therapeutics in a report on Monday, March 17th. They set a “market perform” rating and a $16.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.44.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock opened at $9.14 on Friday. The firm has a market cap of $696.80 million, a PE ratio of -3.16 and a beta of 2.23. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56. The firm’s 50-day simple moving average is $14.03 and its 200-day simple moving average is $19.18.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. The firm had revenue of $18.45 million for the quarter, compared to analysts’ expectations of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter in the prior year, the firm posted ($0.76) earnings per share. On average, equities analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the sale, the chief financial officer now directly owns 39,549 shares of the company’s stock, valued at approximately $785,047.65. This represents a 6.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,326 shares of company stock valued at $213,449 over the last 90 days. 9.80% of the stock is owned by company insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.